Biostem Technologies Inc (BSEM)

$6.74 +0.50 (8.01%)
Market Cap 104.94M
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio 7.91
Forward PE 23.17
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 90,000
Avg Vol 119,018
Day's Range N/A - N/A
Shares Out 16.82M
Stochastic %K 50%
Beta -0.38
Analysts Strong Buy
Price Target $25.50

Company Profile

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the r...

Industry: Biotechnology
Sector: Healthcare
Phone: 954 380 8342
Address:
4901 Northwest 17th Way, Suite 606, Fort Lauderdale, United States
MRSUNNY
MRSUNNY Sep. 4 at 3:08 PM
$BSEM
0 · Reply
VonDooom
VonDooom Aug. 31 at 11:10 PM
$BSEM extremlyy
0 · Reply
VonDooom
VonDooom Aug. 31 at 11:03 PM
$BSEM National commercial footprint with expanding product portfolio...
0 · Reply
Mimarcano
Mimarcano Aug. 31 at 3:53 PM
$BSEM 👀
0 · Reply
ZTRADEZ_LLC
ZTRADEZ_LLC Aug. 26 at 5:38 PM
ON MY RADAR: NASDAQ: $BSEM *Sponsored BioStem Technologies expanded its surgical and wound-care business through the acquisition of BioTissue's Neox® and Clarix® products. Why it has my attention: • ~$29M in 2025 sales from the acquired assets • Expanded hospital and surgical wound-care presence • Broader national commercial footprint • ~$26B estimated underserved U.S. soft-tissue opportunity The Catalyst I Am Watching: Catalyze received FDA 510(k) clearance in June 2026, with a potential commercial launch in Q4 2026 and further regulatory expansion beginning in 2027. Communicated Disclaimer https://ztradez.net/communicated-disclaimer3/
0 · Reply
BullTradeFinder
BullTradeFinder Aug. 26 at 5:11 PM
ON MY RADAR: NASDAQ: $BSEM BioStem Technologies expanded its surgical and wound-care business through the acquisition of BioTissue's Neox® and Clarix® products. Why it has my attention: • ~$29M in 2025 sales from the acquired assets • Expanded hospital and surgical wound-care presence • Broader national commercial footprint • ~$26B estimated underserved U.S. soft-tissue opportunity The Catalyst I Am Watching: Catalyze received FDA 510(k) clearance in June 2026, with a potential commercial launch in Q4 2026 and further regulatory expansion beginning in 2027. Communicated-Disclaimer https://docs.google.com/document/d/1eSvGNsZ8aOX44aVIuHhWw4Hd6RMyLjjolBqd3yVA76c/edit?usp=sharing
0 · Reply
griffinrc23
griffinrc23 Aug. 26 at 2:01 PM
Nasdaq Uplisting (August 7, 2026) $BSEM from OTC to the Nasdaq Capital Market under the same ticker. This was a major capital-markets milestone intended to improve visibility, liquidity, and access to institutional capital. https://biostemtechnologies.com/
0 · Reply
JTE_Theta
JTE_Theta Aug. 26 at 12:30 PM
🚨 $BSEM IS ONE I’M WATCHING CLOSELY BioStem Technologies is quietly expanding its footprint in the wound care market. Here’s what caught my attention: • $29M in 2025 sales from the acquired BioTissue assets • Expansion into hospital + surgical wound care • FDA 510(k) clearance for Catalyze • Potential Q4 2026 launch • Broader commercial reach across the U.S. • Management pursuing a potential Nasdaq uplisting The acquisition also gives $BSEM exposure to a much larger addressable market while adding established products and commercial infrastructure. $BSEM is firmly on my radar. CommunicatedDisclaimer: http://tinyurl.com/ysduw3aj
0 · Reply
Sidoti
Sidoti Aug. 21 at 9:30 AM
BioStem Technologies ($BSEM) Management Team presented this week at the Sidoti Micro-Cap Virtual Conference. Watch the replay here: http://dlvr.it/TV6Nsf
0 · Reply
Biotech80
Biotech80 Aug. 20 at 3:34 PM
$BSEM 💎💎💎💎💎
0 · Reply
Latest News on BSEM
BioStem Technologies reports GPO contract coverage for Vendaje, Vendaje AC

2026-09-04T11:10:10.000Z - 2 days ago

BioStem Technologies reports GPO contract coverage for Vendaje, Vendaje AC

BioStem Technologies Transcript: Micro-Cap Virtual Conference

Aug 19, 2026, 10:45 AM EDT - 18 days ago

BioStem Technologies Transcript: Micro-Cap Virtual Conference

BioStem Technologies Slides: Company presentation

Aug 19, 2026, 7:00 AM EDT - 18 days ago

BioStem Technologies Slides: Company presentation

BioStem Technologies Earnings Call Transcript: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 25 days ago

BioStem Technologies Earnings Call Transcript: Q2 2026

BioStem Technologies Quarterly report: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 25 days ago

BioStem Technologies Quarterly report: Q2 2026

BioStem Technologies Earnings release: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 25 days ago

BioStem Technologies Earnings release: Q2 2026

BioStem files registration statement with SEC, to pursue Nasdaq listing

2026-07-10T11:05:27.000Z - 1 month ago

BioStem files registration statement with SEC, to pursue Nasdaq listing

BioStem Technologies issued four U.S. design patents for allograft technology

2026-07-08T12:15:41.000Z - 2 months ago

BioStem Technologies issued four U.S. design patents for allograft technology

BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies

Jul 8, 2026, 8:00 AM EDT - 2 months ago

BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies

BioStem Technologies announces notice of allowance for four patents

2026-05-20T13:06:23.000Z - 3 months ago

BioStem Technologies announces notice of allowance for four patents

BioStem Technologies price target lowered to $7 from $9 at H.C. Wainwright

2026-05-15T17:08:54.000Z - 3 months ago

BioStem Technologies price target lowered to $7 from $9 at H.C. Wainwright

Biostem Technologies initiated with a Buy at H.C. Wainwright

2026-05-07T03:26:41.000Z - 4 months ago

Biostem Technologies initiated with a Buy at H.C. Wainwright

BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair

Mar 23, 2026, 11:40 AM EDT - 5 months ago

BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair

BioTissue Holdings, Inc Strengthens Strategic Focus on Ocular Innovation with Sale of Surgical and Wound Care Business to BioStem Technologies

Jan 21, 2026, 6:00 PM EST - 7 months ago

BioTissue Holdings, Inc Strengthens Strategic Focus on Ocular Innovation with Sale of Surgical and Wound Care Business to BioStem Technologies

BioStem Technologies Slides: Conference presentation

Jan 10, 2026, 7:00 AM EST - 7 months ago

BioStem Technologies Slides: Conference presentation

BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant

Oct 27, 2025, 4:15 PM EDT - 10 months ago

BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant

BioStem Announces Notice of Allowance for Two U.S. Patent Applications

Mar 31, 2025, 7:00 AM EDT - 1 year ago

BioStem Announces Notice of Allowance for Two U.S. Patent Applications

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

Jan 8, 2025, 7:00 AM EST - 1 year ago

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Technologies CEO to Present at Biotech Showcase 2025

Jan 2, 2025, 7:00 AM EST - 1 year ago

BioStem Technologies CEO to Present at Biotech Showcase 2025

BioStem Technologies to Present at the LD Micro Main Event XVII on Wednesday, October 30, 2024, at 9:30 AM PT

Oct 23, 2024, 7:00 AM EDT - 1 year ago

BioStem Technologies to Present at the LD Micro Main Event XVII on Wednesday, October 30, 2024, at 9:30 AM PT

BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET

Aug 29, 2024, 7:00 AM EDT - 2 years ago

BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET

BioStem Technologies Inc. In A Race To The Top With Innovative Wound-Care Treatments

Jul 16, 2024, 8:12 AM EDT - 2 years ago

BioStem Technologies Inc. In A Race To The Top With Innovative Wound-Care Treatments

UPDATE -- PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion

Jun 17, 2024, 2:07 PM EDT - 2 years ago

UPDATE -- PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion

PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion

Jun 17, 2024, 10:17 AM EDT - 2 years ago

PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion

BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts

Apr 30, 2024, 8:30 AM EDT - 2 years ago

BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts

Center for Medicare Services Established National Pricing of AmnioWrap2™ in All MAC Regions

Dec 14, 2023, 8:30 AM EST - 2 years ago

Center for Medicare Services Established National Pricing of AmnioWrap2™ in All MAC Regions

NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft

Sep 14, 2023, 8:00 AM EDT - 2 years ago

NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft

NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft

Sep 11, 2023, 8:00 AM EDT - 2 years ago

NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft

BioStem Awarded a Spot on ECAT, DAPA, and FSS Contract Vehicles Through SDVOSB, Lovell

Sep 6, 2023, 12:00 PM EDT - 3 years ago

BioStem Awarded a Spot on ECAT, DAPA, and FSS Contract Vehicles Through SDVOSB, Lovell

BioStem Technologies Commends OIG's Recommendation for CMS to Address ASP Reporting Requirements for Skin Substitute Products

Mar 23, 2023, 7:30 AM EDT - 3 years ago

BioStem Technologies Commends OIG's Recommendation for CMS to Address ASP Reporting Requirements for Skin Substitute Products

BioStem Technologies to Acquire Majority of Assets of Auxocell Laboratories, Inc.

Mar 7, 2023, 7:30 AM EST - 3 years ago

BioStem Technologies to Acquire Majority of Assets of Auxocell Laboratories, Inc.

BioStem Technologies Enters Into a Share Exchange Agreement

Feb 14, 2023, 8:55 AM EST - 3 years ago

BioStem Technologies Enters Into a Share Exchange Agreement

BioStem Technologies Poised for Growth with Two New Hires: Michael Sylvester Joins as Vice President of Sales, Neal Bhattacharya as Vice President of Marketing

Feb 1, 2023, 7:30 AM EST - 3 years ago

BioStem Technologies Poised for Growth with Two New Hires: Michael Sylvester Joins as Vice President of Sales, Neal Bhattacharya as Vice President of Marketing

Center for Medicare Services Established National Pricing of VENDAJETM in All MAC regions

Jan 24, 2023, 7:30 AM EST - 3 years ago

Center for Medicare Services Established National Pricing of VENDAJETM in All MAC regions

BioStem Technologies Announces Up-Listing to the OTCQB Venture Market

Dec 16, 2022, 7:30 AM EST - 3 years ago

BioStem Technologies Announces Up-Listing to the OTCQB Venture Market

BioStem Technologies Announces Partnership with Kill Cliff FC

Dec 14, 2022, 7:30 AM EST - 3 years ago

BioStem Technologies Announces Partnership with Kill Cliff FC

BioStem Technologies Reports Third Quarter 2022 Operating and Financial Results

Nov 15, 2022, 4:05 PM EST - 3 years ago

BioStem Technologies Reports Third Quarter 2022 Operating and Financial Results

BioStem Technologies to Host Third Quarter Financial Results and Corporate Update Conference Call

Nov 15, 2022, 7:30 AM EST - 3 years ago

BioStem Technologies to Host Third Quarter Financial Results and Corporate Update Conference Call

BioStem Promotes Michael Fortunato, CPA to Chief Financial Officer

Oct 26, 2022, 7:30 AM EDT - 3 years ago

BioStem Promotes Michael Fortunato, CPA to Chief Financial Officer

BioStem to Present at the Dawson James Securities 2022 Small Cap Growth Conference

Oct 10, 2022, 7:30 AM EDT - 3 years ago

BioStem to Present at the Dawson James Securities 2022 Small Cap Growth Conference

BioStem Announces Publication of a Standardized Method to Evaluate Growth Factor Elution from Placental Tissue Allografts

Sep 13, 2022, 7:30 AM EDT - 3 years ago

BioStem Announces Publication of a Standardized Method to Evaluate Growth Factor Elution from Placental Tissue Allografts

BioStem Technologies Strengthens its Board of Directors and Audit Committee with the Appointment of Accomplished Medtech Financial Leader Brandon Poe

Sep 8, 2022, 7:30 AM EDT - 3 years ago

BioStem Technologies Strengthens its Board of Directors and Audit Committee with the Appointment of Accomplished Medtech Financial Leader Brandon Poe

BioStem Technologies Reports Second Quarter 2022 Operating and Financial Results

Aug 22, 2022, 4:01 PM EDT - 4 years ago

BioStem Technologies Reports Second Quarter 2022 Operating and Financial Results

BioStem Technologies to Host Second Quarter Financial Results and Corporate Update Conference Call on August 22nd

Aug 16, 2022, 7:30 AM EDT - 4 years ago

BioStem Technologies to Host Second Quarter Financial Results and Corporate Update Conference Call on August 22nd

BioStem Technologies® CEO to Appear on the Benzinga All Access Show on June 17,2022

Jun 17, 2022, 9:25 AM EDT - 4 years ago

BioStem Technologies® CEO to Appear on the Benzinga All Access Show on June 17,2022

BioStem Technologies Reports March 31, 2022 Record Quarterly Financial Results

May 16, 2022, 12:25 PM EDT - 4 years ago

BioStem Technologies Reports March 31, 2022 Record Quarterly Financial Results

BioStem Technologies Inc. Reports December 31, 2021 Year End Financial Results

Apr 1, 2022, 10:00 AM EDT - 4 years ago

BioStem Technologies Inc. Reports December 31, 2021 Year End Financial Results

BioStem Technologies Announces Veterans Day Fundraiser to Support America's VetDogs®

Nov 1, 2021, 9:00 AM EDT - 4 years ago

BioStem Technologies Announces Veterans Day Fundraiser to Support America's VetDogs®

BioStem Technologies Reports Record Breaking Second Quarter Sales

Aug 25, 2021, 11:15 AM EDT - 5 years ago

BioStem Technologies Reports Record Breaking Second Quarter Sales

BioStem Technologies, Inc., Announces the Engagement of Biologics Consulting To Support FDA Strategies and Submissions.

Jul 27, 2021, 9:00 AM EDT - 5 years ago

BioStem Technologies, Inc., Announces the Engagement of Biologics Consulting To Support FDA Strategies and Submissions.

BioStem Technologies, Inc. Awarded Q Code for VENDAJE® Product Line From CMS.

Jul 23, 2021, 9:00 AM EDT - 5 years ago

BioStem Technologies, Inc. Awarded Q Code for VENDAJE® Product Line From CMS.

BioStem Technologies Announces Filing of 2021 First Quarter Financial Reports

May 24, 2021, 11:34 AM EDT - 5 years ago

BioStem Technologies Announces Filing of 2021 First Quarter Financial Reports

BioStem Technologies, Inc., Announces the Addition of Three Key Scientific Advisory Board Members

Apr 20, 2021, 9:00 AM EDT - 5 years ago

BioStem Technologies, Inc., Announces the Addition of Three Key Scientific Advisory Board Members

BioStem Technologies, Inc. Announces Launch of National Sales Force Expansion

Apr 15, 2021, 9:00 AM EDT - 5 years ago

BioStem Technologies, Inc. Announces Launch of National Sales Force Expansion

BioStem Technologies, Inc. Reports Financial Results for Fourth Quarter and Fiscal Year 2020

Apr 5, 2021, 9:00 AM EDT - 5 years ago

BioStem Technologies, Inc. Reports Financial Results for Fourth Quarter and Fiscal Year 2020

BioStem Technologies, Inc. Receives TRIP (TRG Rapid Inquiry Program) Response for VENDAJE™

Mar 25, 2021, 9:00 AM EDT - 5 years ago

BioStem Technologies, Inc. Receives TRIP (TRG Rapid Inquiry Program) Response for VENDAJE™

BioStem Technologies Engages D. Brooks & Associates for 2020 and 2019 Audit

Mar 15, 2021, 9:00 AM EDT - 5 years ago

BioStem Technologies Engages D. Brooks & Associates for 2020 and 2019 Audit

BioStem Technologies, Announces Filing of 2020 Quarterly Reports

Dec 24, 2020, 2:00 PM EST - 5 years ago

BioStem Technologies, Announces Filing of 2020 Quarterly Reports

MRSUNNY
MRSUNNY Sep. 4 at 3:08 PM
$BSEM
0 · Reply
VonDooom
VonDooom Aug. 31 at 11:10 PM
$BSEM extremlyy
0 · Reply
VonDooom
VonDooom Aug. 31 at 11:03 PM
$BSEM National commercial footprint with expanding product portfolio...
0 · Reply
Mimarcano
Mimarcano Aug. 31 at 3:53 PM
$BSEM 👀
0 · Reply
ZTRADEZ_LLC
ZTRADEZ_LLC Aug. 26 at 5:38 PM
ON MY RADAR: NASDAQ: $BSEM *Sponsored BioStem Technologies expanded its surgical and wound-care business through the acquisition of BioTissue's Neox® and Clarix® products. Why it has my attention: • ~$29M in 2025 sales from the acquired assets • Expanded hospital and surgical wound-care presence • Broader national commercial footprint • ~$26B estimated underserved U.S. soft-tissue opportunity The Catalyst I Am Watching: Catalyze received FDA 510(k) clearance in June 2026, with a potential commercial launch in Q4 2026 and further regulatory expansion beginning in 2027. Communicated Disclaimer https://ztradez.net/communicated-disclaimer3/
0 · Reply
BullTradeFinder
BullTradeFinder Aug. 26 at 5:11 PM
ON MY RADAR: NASDAQ: $BSEM BioStem Technologies expanded its surgical and wound-care business through the acquisition of BioTissue's Neox® and Clarix® products. Why it has my attention: • ~$29M in 2025 sales from the acquired assets • Expanded hospital and surgical wound-care presence • Broader national commercial footprint • ~$26B estimated underserved U.S. soft-tissue opportunity The Catalyst I Am Watching: Catalyze received FDA 510(k) clearance in June 2026, with a potential commercial launch in Q4 2026 and further regulatory expansion beginning in 2027. Communicated-Disclaimer https://docs.google.com/document/d/1eSvGNsZ8aOX44aVIuHhWw4Hd6RMyLjjolBqd3yVA76c/edit?usp=sharing
0 · Reply
griffinrc23
griffinrc23 Aug. 26 at 2:01 PM
Nasdaq Uplisting (August 7, 2026) $BSEM from OTC to the Nasdaq Capital Market under the same ticker. This was a major capital-markets milestone intended to improve visibility, liquidity, and access to institutional capital. https://biostemtechnologies.com/
0 · Reply
JTE_Theta
JTE_Theta Aug. 26 at 12:30 PM
🚨 $BSEM IS ONE I’M WATCHING CLOSELY BioStem Technologies is quietly expanding its footprint in the wound care market. Here’s what caught my attention: • $29M in 2025 sales from the acquired BioTissue assets • Expansion into hospital + surgical wound care • FDA 510(k) clearance for Catalyze • Potential Q4 2026 launch • Broader commercial reach across the U.S. • Management pursuing a potential Nasdaq uplisting The acquisition also gives $BSEM exposure to a much larger addressable market while adding established products and commercial infrastructure. $BSEM is firmly on my radar. CommunicatedDisclaimer: http://tinyurl.com/ysduw3aj
0 · Reply
Sidoti
Sidoti Aug. 21 at 9:30 AM
BioStem Technologies ($BSEM) Management Team presented this week at the Sidoti Micro-Cap Virtual Conference. Watch the replay here: http://dlvr.it/TV6Nsf
0 · Reply
Biotech80
Biotech80 Aug. 20 at 3:34 PM
$BSEM 💎💎💎💎💎
0 · Reply
Sidoti
Sidoti Aug. 18 at 3:08 PM
See these #healthcare management teams present live and submit your questions during Q&A. $TKNO $ASBP $BSEM http://dlvr.it/TV45vw All investors are welcome to join free of charge: http://dlvr.it/TV45vx
0 · Reply
Sidoti
Sidoti Aug. 17 at 4:11 PM
See these #healthcare management teams present live and submit your questions during Q&A. $TKNO $ASBP $BSEM http://dlvr.it/TV3JSs All investors are welcome to join free of charge: http://dlvr.it/TV3JSv
0 · Reply
idkmikes57
idkmikes57 Aug. 17 at 4:09 PM
$BSEM Haircuts 💇‍♂️
0 · Reply
idkmikes57
idkmikes57 Aug. 17 at 3:47 PM
$BSEM better off on a pink sheet l o l.
0 · Reply
Synaptric
Synaptric Aug. 14 at 12:16 PM
Thursday's move after Wednesday amc earnings. Double-digit gainers came from the Extremely Bullish $RNXT , Bullish $INO , and Neutral $STEM zones. Double-digit losers came from Bullish $CBRS and Bearish $BSEM zones.
0 · Reply
GlobalInsights
GlobalInsights Aug. 13 at 1:47 PM
$BSEM Now that BSEM is on the NASDAQ the quant trading algorithms will determine where the shares trade. No humans involved
0 · Reply
GlobalInsights
GlobalInsights Aug. 13 at 1:44 PM
$BSEM Well Rabbi guess I should have said something negative to help prevent investors in believing in the shady characters running this company. Guess Nasdaq up listing isn’t all it’s cracked up to be.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 12 at 10:08 PM
$BSEM Q2 '26 Earnings Results & Recap BioStem Technologies reported Q2 2026 net revenue of $7.9M, a 28% YoY decrease, driven by CMS reimbursement changes that reduced physician office revenue by 90% compared to Q2 2025.
0 · Reply
ajmrtxl
ajmrtxl Aug. 12 at 4:18 PM
$BSEM 's latest squeeze play
0 · Reply
GlobalInsights
GlobalInsights Aug. 12 at 4:07 AM
$BSEM Earnings release and 10Q should be interesting to see how the business is operating now that they are play by the rules everyone else is. Also, the 10Q will offer investors a lot more information than they reported as a pink sheet company.
0 · Reply
ContrarianCraft
ContrarianCraft Aug. 7 at 4:55 PM
I honestly dont understand the valuation gap between these two RMTG has a better balance sheet better margins better growth and better profits $BSEM is trailing in every category but still trades at a premium it seems like the market hasnt looked at the actual numbers for RMTG yet
0 · Reply
ShortShifter
ShortShifter Aug. 7 at 4:51 PM
What really stands out to me is the equity position of both companies RMTG has positive shareholders equity which means they have a buffer against any downturns $BSEM has a deficit which means they are technically insolvent on paper that is a massive differance in risk profile for anyone looking at the balance sheets
0 · Reply